The DOI matches its Crossref record.
Montelukast, Compared With Fluticasone, for Control of Asthma Among 6- to 14-Year-Old Patients With Mild Asthma: The MOSAIC Study
Abstract
Background. Guidelines recommend daily controller therapy for mild persistent asthma. Montelukast has demonstrated consistent benefit in controlling symptoms of asthma and may be an alternative, orally administered, nonsteroidal agent for treating mild asthma. Methods. The Montelukast Study of Asthma in Children (MOSAIC study) was a 12-month, multicenter, randomized, double-blind, noninferiority trial to determine the effect of once-daily, orally administered montelukast (5 mg) (n = 495), compared with twice-daily, inhaled fluticasone (100 μg) (n = 499), on the percentage of asthma rescue-free days (RFDs) (any day without asthma rescue medication and with no asthma-related resource use). Patients 6 to 14 years of age had mild persistent asthma (average percentage of predicted forced expiratory volume in 1 second: 87.2%; RFDs at baseline: 64%). Montelukast would be considered not inferior to fluticasone if the upper limit of the 95% confidence interval for the difference in mean percentages of RFDs (fluticasone minus montelukast) was above −7% (a difference of ∼2 days/month). Results. The mean percentage of RFDs was 84.0% in the montelukast group and 86.7% in the fluticasone group. The least-squares mean difference was −2.8% (95% confidence interval: −4.7% to −0.9%), within the noninferiority limit of −7%. The proportion of patients requiring systemic corticosteroids and the number of patients with an asthma attack were greater in the montelukast group. Both montelukast and fluticasone were well tolerated. Conclusions. Montelukast was demonstrated to be not inferior to fluticasone in increasing the percentage of RFDs among 6- to 14-year-old patients with mild asthma. Secondary end points, including percentage of predicted forced expiratory volume in 1 second value, days with β-receptor agonist use, and quality of life, improved in both groups but were significantly better in the fluticasone treatment group.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Global strategy for asthma management and prevention: GINA executive summary
Bateman, E. D., Hurd, S. S., Barnes, P. J., Bousquet, J., Drazen, J. M., FitzGerald, M., Gibson, P., Ohta, K., O'Byrne, P., Pedersen, S. E., et al. (2008) · European Respiratory Journal · doi:10.1183/09031936.00138707 · Cited by 3,203
International consensus on (ICON) pediatric asthma
Papadopoulos, N. G., Arakawa, H., Carlsen, K. ‐., Custovic, A., Gern, J., Lemanske, R., Le Souef, P., Mäkelä, M., Roberts, G., Wong, G., et al. (2012) · Allergy · doi:10.1111/j.1398-9995.2012.02865.x · Cited by 455
Lanier, B., Bridges, T., Kulus, M., Taylor, A. F., Berhane, I., & Vidaurre, C. F. (2009) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2009.09.021 · Cited by 360
Chauhan, B. F., & Ducharme, F. M. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002314.pub3 · Cited by 306
Sorkness, C. A., Lemanske, R. F., Mauger, D. T., Boehmer, S. J., Chinchilli, V. M., Martinez, F. D., Strunk, R. C., Szefler, S. J., Zeiger, R. S., Bacharier, L. B., et al. (2007) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2006.09.042 · Cited by 297
Metadata
- Authors
- Garcia Garcia, M. L., Wahn, U., Gilles, L., Swern, A., Tozzi, C. A., & Polos, P.
- Venue
- Pediatrics
- Publisher
- American Academy of Pediatrics (AAP)
- Published
- 2005-08-01
- Volume
- 116
- Issue
- 2
- Pages
- 360-369
- ISSN
- 0031-4005 (ISSN-L)
- 1098-4275
- OpenAlex
- W2132047649
- Cited by
- 181
- References
- 0
- FWCI
- 13.69
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Montelukast, Compared With Fluticasone, for Control of Asthma Among 6- to 14-Year-Old Patients With Mild Asthma: The MOSAIC Study. https://app.cochat.ai/papers/10.1542/peds.2004-1172
- The paper
- Garcia Garcia, M. L., Wahn, U., Gilles, L., Swern, A., Tozzi, C. A., & Polos, P. (2005). Montelukast, Compared With Fluticasone, for Control of Asthma Among 6- to 14-Year-Old Patients With Mild Asthma: The MOSAIC Study. Pediatrics. https://doi.org/10.1542/peds.2004-1172
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.